Worldquant Millennium Advisors LLC Has $86.67 Million Stake in Cencora, Inc. (NYSE:COR)

Worldquant Millennium Advisors LLC increased its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 42.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 385,759 shares of the company's stock after acquiring an additional 114,806 shares during the period. Worldquant Millennium Advisors LLC owned about 0.20% of Cencora worth $86,672,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. iSAM Funds UK Ltd acquired a new stake in shares of Cencora during the fourth quarter worth $1,113,000. Triglav Skladi D.O.O. bought a new position in Cencora in the fourth quarter valued at $3,640,000. Twinbeech Capital LP bought a new position in Cencora in the fourth quarter valued at $12,929,000. Tidal Investments LLC grew its position in Cencora by 3.1% in the fourth quarter. Tidal Investments LLC now owns 21,319 shares of the company's stock valued at $4,790,000 after purchasing an additional 635 shares in the last quarter. Finally, Strategic Wealth Partners Ltd. grew its position in Cencora by 34.2% in the fourth quarter. Strategic Wealth Partners Ltd. now owns 31,749 shares of the company's stock valued at $7,763,000 after purchasing an additional 8,092 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Up 0.7%

Cencora stock opened at $292.37 on Tuesday. The firm has a market capitalization of $56.70 billion, a PE ratio of 41.59, a P/E/G ratio of 1.31 and a beta of 0.60. The company's 50-day moving average is $279.87 and its 200-day moving average is $255.76. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the prior year, the business earned $3.80 EPS. Cencora's quarterly revenue was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Analyst Ratings Changes

A number of research firms recently weighed in on COR. Wells Fargo & Company raised their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. UBS Group raised their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Robert W. Baird raised their target price on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $301.18.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,223 shares of company stock worth $13,580,967. Insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.